about
Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic targetUnderstanding the role of PIN1 in hepatocellular carcinomaNull mutation of the Lmo4 gene or a combined null mutation of the Lmo1/Lmo3 genes causes perinatal lethality, and Lmo4 controls neural tube development in miceDiagnosis and management of extranodal NK/T cell lymphoma nasal type.SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.Extranodal natural-killer/t-cell lymphoma, nasal typeClofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.Intracellular antibody-caspase-mediated cell killing: an approach for application in cancer therapy.Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment resultsTreatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTDThe CDK subunit CKS2 counteracts CKS1 to control cyclin A/CDK2 activity in maintaining replicative fidelity and neurodevelopment.Detection of intrahepatic hepatitis B virus DNA and correlation with hepatic necroinflammation and fibrosis.Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.miR-874-3p is down-regulated in hepatocellular carcinoma and negatively regulates PIN1 expression.Antifungal drug usage in haematologic patients during a 4-year period in an Asian university teaching hospital.T-cell lymphoma: Microenvironment-related biomarkers.Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma.Chidamide in the treatment of peripheral T-cell lymphomaThe diagnosis and management of NK/T-cell lymphomas.Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism.Pembrolizumab (Keytruda)PIN1 expression contributes to hepatic carcinogenesis.PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients.Management of advanced NK/T-cell lymphoma.Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves' disease.Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group.HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.Synchronous Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly and Epstein-Barr virus-positive classical Hodgkin lymphoma.Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.Valganciclovir thrice weekly for prophylaxis against cytomegalovirus reactivation during alemtuzumab therapy.T-cell large granular lymphocyte leukemia: an Asian perspective.The peptidyl-prolyl isomerase PIN1 relieves cyclin-dependent kinase 2 (CDK2) inhibition by the CDK inhibitor p27.Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.Deficiency of Cks1 Leads to Learning and Long-Term Memory Defects and p27 Dependent Formation of Neuronal Cofilin Aggregates.Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma.
P50
Q26822550-A44CE6EE-1CCA-43B4-886F-F8CF4D75F739Q28073477-941B38BB-5F78-4926-B635-DE35F4EDF1B0Q28587181-40E2B197-840C-405F-ABA0-5A9BE1477340Q30249309-413D1D9E-3039-4B2D-8A7C-4A3E6B1204E4Q33402956-E87EC940-3E43-479C-8C82-78B59AAC3A7BQ34479166-AB0F2B19-E747-4C67-8B16-8EC58D157376Q35278018-4A36D0D0-41C8-4F84-BC76-B4162634AF94Q35418257-C2D51D05-ED68-483C-88A9-75511958B277Q35534203-1ECE9D22-7A19-4B14-8076-C75080060AD8Q36162623-A1CCB338-3761-45C6-8A44-5C5E2019C870Q37501709-B6842268-7617-4451-B048-3EBBDB9E3649Q37511323-D90D59B5-E329-4D87-8E57-062DFF0E37A5Q37616347-A2E36A13-BD10-43BB-B998-627BDF3CFE11Q37706910-363F9D8C-746E-4179-927F-7C747717AF1DQ38070844-79B39568-CD3A-42F7-BC6D-E871493BD891Q38521971-0482D72B-7762-4FFA-B76E-53FBE3A1DC09Q38692997-9E927E96-237C-4901-8A24-6FC090F226B4Q38877924-78DE888E-6EEA-4255-880C-D26592FA98E8Q38917500-94E1F9A4-8D59-4454-A545-BA7696E10392Q39110404-1EC4817B-6E67-4FAF-BBF0-FA833ADC93E7Q39243241-387ADFAD-EE5A-4647-9B4B-6B697D44D344Q39410927-E028EE4C-1013-4E94-8C5C-0AB52F37C1A6Q39615516-FB3E246A-FDAF-4265-8B79-F28BC335FB49Q40255809-D9CB6626-7F29-4359-AE36-CF4FD9F90CD6Q40336693-F9BA27E7-BEF4-4FD5-8394-416FB21AFA54Q40441267-7478C9E7-38F4-4ECE-97B5-64FE4F3ED124Q42212820-468B0505-A569-4E6C-AA81-08B867B25FD6Q42238296-03DC1D3F-3DFB-4E11-9CE9-7AD1C7053D7FQ42565122-D87DC68D-9D40-4D03-905D-2F56790F154CQ44149618-00B489F5-B452-4B03-9D23-44EC805E96D3Q44927737-57AFBCAE-A459-4E6B-8FAC-9209C203E651Q45363698-656EB434-08A0-4BE9-8420-F0A19EC29E34Q46065723-A4A502E2-4BA3-45B6-94C9-A922DC9C1264Q46325064-F3829BAC-0712-4618-B34F-32F4488789F3Q46449990-A0A6240B-EF55-4B5E-9BAE-3519B0AB2C60Q47423700-445BC532-7A80-4DAA-814F-EFA7F663E5F4Q47686516-1304C215-A78B-432B-ADBE-1EF43F613CF8Q48114756-1BEA9BF7-32C6-4D03-91B3-0B048830A24CQ48235278-8B4862B8-0D47-4199-A908-FBF4784521FBQ48264091-80CC80A7-8D65-4042-9D26-7DB6362BB3D4
P50
description
medical researcher in Hong Kong
@en
wetenschapper
@nl
name
Eric Tse
@en
Tse E
@nl
type
label
Eric Tse
@en
Tse E
@nl
altLabel
Eric Wai Choi Tse
@en
Tse E
@en
prefLabel
Eric Tse
@en
Tse E
@nl
P106
P31
P496
0000-0002-8351-4722